Pembrolizumab vs Risankizumab

## Pembrolizumab vs Risankizumab: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Risankizumab**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Risankizumab — N/A.

## Chemical Properties

**Type**: Pembrolizumab — Antibody; Risankizumab — Antibody.